ADMA BIOLOGICS, INC.
RAMSEY, NJ

ADMA Biologics, Inc. is a Florida-based biopharmaceutical company founded in 2007 with a steadfast commitment to developing superior products for immunodeficient patients at risk of infection. The company focuses on human connection, striving to transform groundbreaking scientific research into meaningful actions that significantly impact patient care. Through relentless dedication and innovation, ADMA Biologics is advancing the field of immunotechnology by developing plasma-derived products primarily through direct R&D efforts and strategic licensing opportunities. The company's product pipeline includes infectious disease-specific intravenous immune globulin (IVIG) candidates targeting both primary immunodeficiency disorder (PIDD) patients and transplant recipients. Future projects aim to address chronic viral and bacterial infections, enhancing the quality of life for its specialized patient demographic. ADMA Biologics' unique culture is driven by a management team with diverse yet complementary backgrounds characterized by innate curiosity and entrepreneurial spirit. The executive leadership includes Adam S. Grossman as President and CEO, bringing over 20 years of experience in the blood and plasma industry from his roles at National Hospital Specialties, GenesisBPS, MedImmune, Inc., and the American Red Cross. Other key leaders are Brian Lenz, who joined the company as VP and CFO in May 2012, contributing extensive financial and operational expertise from stints at CorMedix Inc. and Arno Therapeutics, among others. Dr. Jerrold B. Grossman, ADMA’s Vice-Chairman and Adam's father, brings more than three decades of insight into the blood and plasma sectors as well as leadership qualities that have steered various industry associations. The company is officially registered under Florida corporate status with an incorporation date of August 15, 2017. Located in Ramsey, NJ, it serves clients nationwide from its mailing address at 465 State Rt. 17. Contact numbers for the organization include (201) 478-5552, (561) 989-5800 among others, and more information can be found on their website: admabiologics.com. Their commitment to high-caliber research, exceptional patient care strategies, and continuous innovation positions ADMA Biologics as a pioneering organization in the biopharmaceutical landscape.